SCHEMBL4497808

SCHEMBL4497808

CC(=O)c1ccc(-c2ccc3c(N)n[nH]c3c2)cc1

nearest known ligand 0.63

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 10/20 0.63
BCR P11274 10/20 0.63
JAK2 O60674 2/20 0.62
PDPK1 O15530 5/20 0.60
PRKAB2 O43741 1/20 0.53
PRKAG1 P54619 1/20 0.53
PRKAA2 P54646 1/20 0.53
PRKAA1 Q13131 1/20 0.53
PRKAG3 Q9UGI9 1/20 0.53
PRKAG2 Q9UGJ0 1/20 0.53
PRKAB1 Q9Y478 1/20 0.53
SRC P12931 1/20 0.50
MAPK14 Q16539 1/20 0.50
SGK1 O00141 2/20 0.49
AURKA O14965 1/20 0.49
TGFBR1 P36897 1/20 0.49
ROCK1 Q13464 1/20 0.49
AURKB Q96GD4 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4404646 0.87 PDPK1 (0.51) ABL1BCRJAK2PDPK1PRKAB2
SCHEMBL12907256 0.86 JAK2 (0.69) ABL1BCRJAK2PDPK1SGK1
SCHEMBL7261519 0.82 JAK2 (0.59) ABL1BCRJAK2PDPK1SGK1
SCHEMBL7261517 0.82 JAK2 (0.59) ABL1BCRJAK2PDPK1SGK1
SCHEMBL3359710 0.79 FGFR1 (0.72) ABL1BCRJAK2PDPK1AURKA
SCHEMBL6479941 0.79 JAK2 (0.72) ABL1BCRJAK2PDPK1SGK1
SCHEMBL421269 0.79 JAK2 (0.77) ABL1BCRJAK2PDPK1SGK1
SCHEMBL4404641 0.78 JAK2 (0.58) JAK2PDPK1
SCHEMBL12907241 0.77 JAK2 (1.00) JAK2PDPK1SGK1AURKATGFBR1
SCHEMBL3361070 0.77 JAK2 (1.00) JAK2PDPK1SGK1AURKATGFBR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1506176-B1 AMINOINDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM PFIZER ITALIA SRL (IT) 2013-04-24 EP disclosed
US-7632854-B2 Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them PFIZER ITALIA S.R.L. (IT) 2009-12-15 US disclosed
US-20060106083-A1 Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them PHARMACIA ITALIA S.P.A. (IT) 2006-05-18 US disclosed
EP-1506176-A1 AMINOINDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM Pharmacia Italia S.p.A. (IT) 2005-02-16 EP disclosed
WO-2003097610-A1 AMINOINDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM PHARMACIA ITALIA S.P.A. (IT) 2003-11-27 WO disclosed
WO-2003051847-A1 (1-H-INDAZOL-3-YL) -AMIDE DERIVATIVES AS GSK-3 INHIBITORS SMITHKLINE BEECHAM P.L.C. (GB) 2003-06-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060106083-A1 Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them MAP3K15, MAP3K3, MAP3K20 ABL1 155/4885BCR 1348/4885JAK2 416/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.